Article Type
Changed
Mon, 01/14/2019 - 11:03
Display Headline
Can vaginal misoprostol be administered 1 to 3 days after mifepristone without loss of efficacy or an increase in adverse events?

BACKGROUND: The United States Food and Drug Administration (FDA) has approved the use of mifepristone (RU 486) in a protocol for early medical abortion.1 In that protocol, 600 μg of mifepristone is followed by 400 μg of oral misoprostol 48 hours later. Previous studies have shown that low-dose mifepristone (200 μg) followed 2 days later by 800 μg vaginal misoprostol has fewer side effects and is more effective than the approved protocol. Restricting administration of vaginal misoprostol to a narrow time window 2 days after the mifepristone dose may be inconvenient or unsafe.

POPULATION STUDIED: Healthy pregnant women aged 18 years and older who desired abortions were recruited from 16 sites including hospitals, abortion clinics, family practice offices, and gynecology offices. A total of 2295 women were recruited, and all underwent a transvaginal ultrasound to rule out ectopic pregnancy and to confirm fetal size consistent with a gestation of 56 days or less.

STUDY DESIGN AND VALIDITY: This is an unblinded randomized controlled trial with 3 arms. Subjects were assigned by concealed computer-generated randomization to self-administered 800 μg misoprostol vaginally either 1 (n=745), 2 (n=778), or 3 (n=772) days after a 200-μg dose of mifepristone.

OUTCOMES MEASURED: Complete medical abortion without surgical intervention was the primary outcome.

RESULTS: There was no statistically significant difference in the percentage of women who had complete medical abortions across the 3 groups. The percentages of complete medical abortions for the day 1 and day 2 groups were both 98% (95% confidence interval [CI], 97%-99%), and for the day 3 group it was 96% (95% CI, 95%-97%).

RECOMMENDATIONS FOR CLINICAL PRACTICE

Low-dose mifepristone (200 μg) followed 1 to 3 days later by 800 μg of self-administered vaginal misoprostol is a safe and effective procedure for early medical abortion. Rigid adherence to the oral administration of misoprostol in a medical office 48 hours after mifepristone is not necessary either from a safety or efficacy perspective. Administration of misoprostol 1 or 2 days after mifepristone is preferable, since patients in the day 3 group found the wait less acceptable. Information is available on the Internet about FDA special requirements and approved protocols involving mifepristone.1

Author and Disclosure Information

Caroline R. Richardson, MD
University of Michigan, Ann Arbor E-mail: Caroli@umich.edu

Issue
The Journal of Family Practice - 50(01)
Publications
Topics
Page Number
9
Sections
Author and Disclosure Information

Caroline R. Richardson, MD
University of Michigan, Ann Arbor E-mail: Caroli@umich.edu

Author and Disclosure Information

Caroline R. Richardson, MD
University of Michigan, Ann Arbor E-mail: Caroli@umich.edu

BACKGROUND: The United States Food and Drug Administration (FDA) has approved the use of mifepristone (RU 486) in a protocol for early medical abortion.1 In that protocol, 600 μg of mifepristone is followed by 400 μg of oral misoprostol 48 hours later. Previous studies have shown that low-dose mifepristone (200 μg) followed 2 days later by 800 μg vaginal misoprostol has fewer side effects and is more effective than the approved protocol. Restricting administration of vaginal misoprostol to a narrow time window 2 days after the mifepristone dose may be inconvenient or unsafe.

POPULATION STUDIED: Healthy pregnant women aged 18 years and older who desired abortions were recruited from 16 sites including hospitals, abortion clinics, family practice offices, and gynecology offices. A total of 2295 women were recruited, and all underwent a transvaginal ultrasound to rule out ectopic pregnancy and to confirm fetal size consistent with a gestation of 56 days or less.

STUDY DESIGN AND VALIDITY: This is an unblinded randomized controlled trial with 3 arms. Subjects were assigned by concealed computer-generated randomization to self-administered 800 μg misoprostol vaginally either 1 (n=745), 2 (n=778), or 3 (n=772) days after a 200-μg dose of mifepristone.

OUTCOMES MEASURED: Complete medical abortion without surgical intervention was the primary outcome.

RESULTS: There was no statistically significant difference in the percentage of women who had complete medical abortions across the 3 groups. The percentages of complete medical abortions for the day 1 and day 2 groups were both 98% (95% confidence interval [CI], 97%-99%), and for the day 3 group it was 96% (95% CI, 95%-97%).

RECOMMENDATIONS FOR CLINICAL PRACTICE

Low-dose mifepristone (200 μg) followed 1 to 3 days later by 800 μg of self-administered vaginal misoprostol is a safe and effective procedure for early medical abortion. Rigid adherence to the oral administration of misoprostol in a medical office 48 hours after mifepristone is not necessary either from a safety or efficacy perspective. Administration of misoprostol 1 or 2 days after mifepristone is preferable, since patients in the day 3 group found the wait less acceptable. Information is available on the Internet about FDA special requirements and approved protocols involving mifepristone.1

BACKGROUND: The United States Food and Drug Administration (FDA) has approved the use of mifepristone (RU 486) in a protocol for early medical abortion.1 In that protocol, 600 μg of mifepristone is followed by 400 μg of oral misoprostol 48 hours later. Previous studies have shown that low-dose mifepristone (200 μg) followed 2 days later by 800 μg vaginal misoprostol has fewer side effects and is more effective than the approved protocol. Restricting administration of vaginal misoprostol to a narrow time window 2 days after the mifepristone dose may be inconvenient or unsafe.

POPULATION STUDIED: Healthy pregnant women aged 18 years and older who desired abortions were recruited from 16 sites including hospitals, abortion clinics, family practice offices, and gynecology offices. A total of 2295 women were recruited, and all underwent a transvaginal ultrasound to rule out ectopic pregnancy and to confirm fetal size consistent with a gestation of 56 days or less.

STUDY DESIGN AND VALIDITY: This is an unblinded randomized controlled trial with 3 arms. Subjects were assigned by concealed computer-generated randomization to self-administered 800 μg misoprostol vaginally either 1 (n=745), 2 (n=778), or 3 (n=772) days after a 200-μg dose of mifepristone.

OUTCOMES MEASURED: Complete medical abortion without surgical intervention was the primary outcome.

RESULTS: There was no statistically significant difference in the percentage of women who had complete medical abortions across the 3 groups. The percentages of complete medical abortions for the day 1 and day 2 groups were both 98% (95% confidence interval [CI], 97%-99%), and for the day 3 group it was 96% (95% CI, 95%-97%).

RECOMMENDATIONS FOR CLINICAL PRACTICE

Low-dose mifepristone (200 μg) followed 1 to 3 days later by 800 μg of self-administered vaginal misoprostol is a safe and effective procedure for early medical abortion. Rigid adherence to the oral administration of misoprostol in a medical office 48 hours after mifepristone is not necessary either from a safety or efficacy perspective. Administration of misoprostol 1 or 2 days after mifepristone is preferable, since patients in the day 3 group found the wait less acceptable. Information is available on the Internet about FDA special requirements and approved protocols involving mifepristone.1

Issue
The Journal of Family Practice - 50(01)
Issue
The Journal of Family Practice - 50(01)
Page Number
9
Page Number
9
Publications
Publications
Topics
Article Type
Display Headline
Can vaginal misoprostol be administered 1 to 3 days after mifepristone without loss of efficacy or an increase in adverse events?
Display Headline
Can vaginal misoprostol be administered 1 to 3 days after mifepristone without loss of efficacy or an increase in adverse events?
Sections
Disallow All Ads